IGC Pharma

IGC Pharma R&D per Employee

The R&D Spending per Employee of IGC Pharma (IGC) as of Nov 12, 2026 is 167,516.13 USD. In the previous year, R&D Spending per Employee was 117,903.23 USD — a change of 42.08% (higher).

R&D per Employee

167,516.13USD

YoY

42.08%

Last updated:

R&D Spending per Employee of IGC Pharma is 2026 167,516.13 USD. R&D Spending per Employee of IGC Pharma was 2025 117,903.23 USD. It decreases by 42.08% higher compared to the previous year.

The IGC Pharma R&D per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D per Employee
Date
R&D per Employee
Jan 1, 2019
40,516.13 USD
Jan 1, 2020
32,612.90 USD
Jan 1, 2021
29,967.74 USD
Jan 1, 2022
75,161.29 USD
Jan 1, 2023
111,645.16 USD
Jan 1, 2024
121,709.68 USD
Jan 1, 2025
117,903.23 USD
Jan 1, 2026
167,516.13 USD
The IGC Pharma R&D per Employee history
YEARR&D per EmployeeYoY
167,516.13USD+42.08%
117,903.23USD-3.13%
121,709.68USD+9.01%
111,645.16USD+48.54%
75,161.29USD+150.81%
29,967.74USD-8.11%
32,612.90USD-19.51%
40,516.13USD+816.79%
4,419.35USD+20.18%
3,677.42USD-16.79%
4,419.35USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

IGC Pharma Stock analysis

What does IGC Pharma do? India Globalization Capital Inc. (IGC) is a Maryland-based company that focuses on the development, marketing, and sale of natural supplements, novel cannabis formulations, food and beverages, and the manufacturing of medical devices. IGC was established in 2005 and initially operated as a construction company in India. However, over the years, the company has evolved into a diversified company based in Maryland due to its innovative products and services. One of IGC's most well-known divisions is IGC Pharma, which focuses on cannabis-based medical formulations and medical devices. IGC holds patent applications for certain cannabis-based products and was one of the first companies to explore the use of cannabis as a potential treatment for Alzheimer's patients. In collaboration with the Institute for Medicine and the Origins of Infancy at the University of Maryland, IGC developed a novel THC-based medication for the treatment of spasms, pain, and other symptoms in multiple sclerosis patients. IGC has also developed the "Hyalolex" product, which is made from specific cannabinoids such as CBD. This preparation is available in Germany under the trade name "Cannabidiol Hexal." Hyalolex is available as a dietary supplement and has been proven effective in improving memory performance, attention, and cognitive abilities in Alzheimer's patients. IGC also operates the IGC Nutraceuticals division, which focuses on the manufacturing and marketing of high-quality natural products. These include vitamins, minerals, dietary supplements, and natural herbal supplements that promote physical and mental well-being and support healthy bodily processes. Some of IGC Nutraceuticals' products include Saffron for Depression Relief, the calcium and magnesium formulation, and Bharat Diagnostics. IGC will continue to invest in various fields, including cannabis-based pain relief, dementia treatments, electrochemical energy storage, and the manufacturing of devices that utilize natural resources such as coal and ore. Overall, IGC has become a diversified company that focuses on a variety of industries. IGC has been a pioneer in the cannabis industry and has gained a good reputation through innovative formulations and patents. By expanding into new industries and investing in new technologies, IGC will continue to stay at the forefront of innovation and strengthen its position as one of the emerging development companies in today's economy. IGC Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about IGC Pharma stock

R&D Spending per Employee of IGC Pharma is 167,516.13 USD in 2026.

R&D Spending per Employee of IGC Pharma changed from 117,903.23 USD to 167,516.13 USD, representing a 42.08% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of R&D Spending per Employee IGC Pharma since 2006 – with annual values, charts, and detailed analysis.

R&D per employee shows the research and development investment allocated per employee. Higher values indicate innovation-focused companies.

R&D Spending per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track R&D Spending per Employee's IGC Pharma historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — IGC Pharma

All Key Metrics — IGC Pharma